Hector Tamez1, Duane S Pinto1, Ajay J Kirtane2, Claire Litherland3, Robert W Yeh1, George D Dangas4, Roxana Mehran4, Efthymios N Deliargyris5, Guillermo Ortiz1, C Michael Gibson1, Gregg W Stone3. 1. Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 2. Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York3Associate Editor, JAMA Cardiology. 3. Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York. 4. Mount Sinai Medical Center, New York, New York. 5. The Medicines Company, Parsippany, New Jersey.
Abstract
Importance: Bivalirudin has been associated with reduced bleeding and mortality during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI). However, increased rates of acute stent thrombosis (AST) have been noted when bivalirudin is discontinued at the end of the procedure, which is perhaps related to this medication's short half-life. Objectives: To evaluate the clinical effect of procedure duration on AST when either bivalirudin or heparin plus glycoprotein IIb/IIIa receptor inhibitor (GPI) is used. Design, Setting, and Participants: An ad hoc analysis of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) clinical trial was performed between March 1, 2015, and April 30, 2016, on patients who underwent primary percutaneous coronary intervention with stents and were randomized 1:1 to bivalirudin or heparin plus GPI. Defined as the difference between the patient's arrival at the catheterization laboratory and the patient's final angiogram. Participants included 3602 patients with STEMI, aged 18 years or older, who were undergoing primary percutaneous coronary intervention and presenting less than 12 hours from symptom onset. Main Outcomes and Measures: Clinical events committee-adjudicated definite AST (occurring ≤24 hours after percutaneous coronary intervention). Results: Among patients included in this analysis, procedure time was identified in 1286 receiving bivalirudin and 1412 receiving heparin plus GPI. Shorter procedures were defined as the lowest quartile of duration (<45 minutes). Patients undergoing shorter procedures were younger and less likely to be hypertensive and smokers. Shorter procedures were less complicated with fewer stents implanted, less multivessel stenting, less thrombus, and less no-reflow. An increased risk of definite AST was associated with shorter than with longer procedures with bivalirudin (7 [2.1%] vs 7 [0.7%]; relative risk, 2.87; 95% CI, 1.01-8.17; P = .04) but not with heparin plus GPI (0 vs 3 [0.3%]; P = .30). Conclusions and Relevance: Despite less procedural complexity, shorter primary percutaneous coronary intervention time was associated with an increased risk of AST in patients treated with bivalirudin but not patients treated with heparin plus GPI, possibly because of the rapid offset of bivalirudin's antithrombotic effect during a window of limited oral antiplatelet action. Trial Registration: clinicaltrials.gov Identifier: NCT00433966.
RCT Entities:
Importance: Bivalirudin has been associated with reduced bleeding and mortality during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI). However, increased rates of acute stent thrombosis (AST) have been noted when bivalirudin is discontinued at the end of the procedure, which is perhaps related to this medication's short half-life. Objectives: To evaluate the clinical effect of procedure duration on AST when either bivalirudin or heparin plus glycoprotein IIb/IIIa receptor inhibitor (GPI) is used. Design, Setting, and Participants: An ad hoc analysis of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) clinical trial was performed between March 1, 2015, and April 30, 2016, on patients who underwent primary percutaneous coronary intervention with stents and were randomized 1:1 to bivalirudin or heparin plus GPI. Defined as the difference between the patient's arrival at the catheterization laboratory and the patient's final angiogram. Participants included 3602 patients with STEMI, aged 18 years or older, who were undergoing primary percutaneous coronary intervention and presenting less than 12 hours from symptom onset. Main Outcomes and Measures: Clinical events committee-adjudicated definite AST (occurring ≤24 hours after percutaneous coronary intervention). Results: Among patients included in this analysis, procedure time was identified in 1286 receiving bivalirudin and 1412 receiving heparin plus GPI. Shorter procedures were defined as the lowest quartile of duration (<45 minutes). Patients undergoing shorter procedures were younger and less likely to be hypertensive and smokers. Shorter procedures were less complicated with fewer stents implanted, less multivessel stenting, less thrombus, and less no-reflow. An increased risk of definite AST was associated with shorter than with longer procedures with bivalirudin (7 [2.1%] vs 7 [0.7%]; relative risk, 2.87; 95% CI, 1.01-8.17; P = .04) but not with heparin plus GPI (0 vs 3 [0.3%]; P = .30). Conclusions and Relevance: Despite less procedural complexity, shorter primary percutaneous coronary intervention time was associated with an increased risk of AST in patients treated with bivalirudin but not patients treated with heparin plus GPI, possibly because of the rapid offset of bivalirudin's antithrombotic effect during a window of limited oral antiplatelet action. Trial Registration: clinicaltrials.gov Identifier: NCT00433966.
Authors: Deepak L Bhatt; Gregg W Stone; Kenneth W Mahaffey; C Michael Gibson; P Gabriel Steg; Christian W Hamm; Matthew J Price; Sergio Leonardi; Dianne Gallup; Ezio Bramucci; Peter W Radke; Petr Widimský; Frantisek Tousek; Jeffrey Tauth; Douglas Spriggs; Brent T McLaurin; Dominick J Angiolillo; Philippe Généreux; Tiepu Liu; Jayne Prats; Meredith Todd; Simona Skerjanec; Harvey D White; Robert A Harrington Journal: N Engl J Med Date: 2013-03-10 Impact factor: 91.245
Authors: Gregg W Stone; Roxana Mehran; Patrick Goldstein; Bernhard Witzenbichler; Arnoud Van't Hof; Giulio Guagliumi; Christian W Hamm; Philippe Généreux; Peter Clemmensen; Stuart J Pocock; Bernard J Gersh; Debra Bernstein; Efthymios N Deliargyris; Philippe Gabriel Steg Journal: J Am Coll Cardiol Date: 2015-01-06 Impact factor: 24.094
Authors: Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran Journal: N Engl J Med Date: 2008-05-22 Impact factor: 91.245
Authors: Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables Journal: Lancet Date: 2014-07-04 Impact factor: 79.321